CASI Pharmaceuticals Inc (CASI) - Financial and Strategic SWOT Analysis Review
CASI Pharmaceuticals Inc (CASI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
CASI Pharmaceuticals Inc (CASI) is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapies for treating cancer and other unmet medical needs. The company’s product EVOMELA (melphalan for injection) an intravenous formulation for the treatment of multiple myeloma. Its pipeline product portfolio includes CID-103 for treatment of multiple myeloma; CNTC 19 for hematological malignancies; ZEVALIN for treatment of relapsed/refractory, low-grade B-cell non-Hodgkin’s lymphoma (NHL); MARQIBO for treatment of Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL); BI-1206 for non-hodgkin's lymphoma and solid tumors; CB-5339 AML/MDS and solid tumors; Octreotide LAI for treatment of acromegaly and symptoms associated with neuroendocrine tumors. The company operates subsidiaries in the US and China and a research and development center in Beijing, China. CASI is headquartered in Rockville, Maryland, the US.
CASI Pharmaceuticals Inc Key Recent Developments
May 13,2021: CASI Pharmaceuticals Announces First Quarter 2021 Financial Results
May 11,2021: CASI Pharmaceuticals To Report First Quarter 2021 Financial Results And Host Conference Call May 13, 2021
Mar 30,2021: CASI Pharmaceuticals Announces Full Year 2020 Financial Results
Feb 16,2021: CASI Pharmaceuticals Announces Preliminary Fourth Quarter And Full-Year 2020 Revenues And Provides Business Updates
Dec 16,2020: CASI Pharmaceuticals announces appointment Of Chief Financial Officer
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
CASI Pharmaceuticals Inc (CASI) is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapies for treating cancer and other unmet medical needs. The company’s product EVOMELA (melphalan for injection) an intravenous formulation for the treatment of multiple myeloma. Its pipeline product portfolio includes CID-103 for treatment of multiple myeloma; CNTC 19 for hematological malignancies; ZEVALIN for treatment of relapsed/refractory, low-grade B-cell non-Hodgkin’s lymphoma (NHL); MARQIBO for treatment of Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL); BI-1206 for non-hodgkin's lymphoma and solid tumors; CB-5339 AML/MDS and solid tumors; Octreotide LAI for treatment of acromegaly and symptoms associated with neuroendocrine tumors. The company operates subsidiaries in the US and China and a research and development center in Beijing, China. CASI is headquartered in Rockville, Maryland, the US.
CASI Pharmaceuticals Inc Key Recent Developments
May 13,2021: CASI Pharmaceuticals Announces First Quarter 2021 Financial Results
May 11,2021: CASI Pharmaceuticals To Report First Quarter 2021 Financial Results And Host Conference Call May 13, 2021
Mar 30,2021: CASI Pharmaceuticals Announces Full Year 2020 Financial Results
Feb 16,2021: CASI Pharmaceuticals Announces Preliminary Fourth Quarter And Full-Year 2020 Revenues And Provides Business Updates
Dec 16,2020: CASI Pharmaceuticals announces appointment Of Chief Financial Officer
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
SECTION 1 - ABOUT THE COMPANY
CASI Pharmaceuticals Inc - Key Facts
CASI Pharmaceuticals Inc - Key Employees
CASI Pharmaceuticals Inc - Key Employee Biographies
CASI Pharmaceuticals Inc - Major Products and Services
CASI Pharmaceuticals Inc - History
CASI Pharmaceuticals Inc - Company Statement
CASI Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
CASI Pharmaceuticals Inc - Business Description
R&D Overview
CASI Pharmaceuticals Inc - Corporate Strategy
CASI Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
CASI Pharmaceuticals Inc - Strengths
CASI Pharmaceuticals Inc - Weaknesses
CASI Pharmaceuticals Inc - Opportunities
CASI Pharmaceuticals Inc - Threats
CASI Pharmaceuticals Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
CASI Pharmaceuticals Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
May 13, 2021: CASI Pharmaceuticals Announces First Quarter 2021 Financial Results
May 11, 2021: CASI Pharmaceuticals To Report First Quarter 2021 Financial Results And Host Conference Call May 13, 2021
Mar 30, 2021: CASI Pharmaceuticals Announces Full Year 2020 Financial Results
Feb 16, 2021: CASI Pharmaceuticals Announces Preliminary Fourth Quarter And Full-Year 2020 Revenues And Provides Business Updates
Dec 16, 2020: CASI Pharmaceuticals announces appointment Of Chief Financial Officer
Nov 09, 2020: CASI Pharmaceuticals announces third quarter 2020 financial results
Aug 10, 2020: CASI Pharmaceuticals announces second quarter 2020 financial results
Apr 27, 2020: CASI Pharmaceuticals receives loan under Paycheck Protection Program
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
CASI Pharmaceuticals Inc - Key Facts
CASI Pharmaceuticals Inc - Key Employees
CASI Pharmaceuticals Inc - Key Employee Biographies
CASI Pharmaceuticals Inc - Major Products and Services
CASI Pharmaceuticals Inc - History
CASI Pharmaceuticals Inc - Company Statement
CASI Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
CASI Pharmaceuticals Inc - Business Description
R&D Overview
CASI Pharmaceuticals Inc - Corporate Strategy
CASI Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
CASI Pharmaceuticals Inc - Strengths
CASI Pharmaceuticals Inc - Weaknesses
CASI Pharmaceuticals Inc - Opportunities
CASI Pharmaceuticals Inc - Threats
CASI Pharmaceuticals Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
CASI Pharmaceuticals Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
May 13, 2021: CASI Pharmaceuticals Announces First Quarter 2021 Financial Results
May 11, 2021: CASI Pharmaceuticals To Report First Quarter 2021 Financial Results And Host Conference Call May 13, 2021
Mar 30, 2021: CASI Pharmaceuticals Announces Full Year 2020 Financial Results
Feb 16, 2021: CASI Pharmaceuticals Announces Preliminary Fourth Quarter And Full-Year 2020 Revenues And Provides Business Updates
Dec 16, 2020: CASI Pharmaceuticals announces appointment Of Chief Financial Officer
Nov 09, 2020: CASI Pharmaceuticals announces third quarter 2020 financial results
Aug 10, 2020: CASI Pharmaceuticals announces second quarter 2020 financial results
Apr 27, 2020: CASI Pharmaceuticals receives loan under Paycheck Protection Program
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
LIST OF TABLES
CASI Pharmaceuticals Inc, Key Facts
CASI Pharmaceuticals Inc, Key Employees
CASI Pharmaceuticals Inc, Key Employee Biographies
CASI Pharmaceuticals Inc, Major Products and Services
CASI Pharmaceuticals Inc, History
CASI Pharmaceuticals Inc, Other Locations
CASI Pharmaceuticals Inc, Subsidiaries
CASI Pharmaceuticals Inc, Key Competitors
CASI Pharmaceuticals Inc, Ratios based on current share price
CASI Pharmaceuticals Inc, Annual Ratios
CASI Pharmaceuticals Inc, Annual Ratios (Cont...1)
CASI Pharmaceuticals Inc, Interim Ratios
CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
CASI Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
CASI Pharmaceuticals Inc, Key Facts
CASI Pharmaceuticals Inc, Key Employees
CASI Pharmaceuticals Inc, Key Employee Biographies
CASI Pharmaceuticals Inc, Major Products and Services
CASI Pharmaceuticals Inc, History
CASI Pharmaceuticals Inc, Other Locations
CASI Pharmaceuticals Inc, Subsidiaries
CASI Pharmaceuticals Inc, Key Competitors
CASI Pharmaceuticals Inc, Ratios based on current share price
CASI Pharmaceuticals Inc, Annual Ratios
CASI Pharmaceuticals Inc, Annual Ratios (Cont...1)
CASI Pharmaceuticals Inc, Interim Ratios
CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
CASI Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
LIST OF FIGURES
CASI Pharmaceuticals Inc, Performance Chart (2016 - 2020)
CASI Pharmaceuticals Inc, Ratio Charts
CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021
CASI Pharmaceuticals Inc, Performance Chart (2016 - 2020)
CASI Pharmaceuticals Inc, Ratio Charts
CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021